AbbVie Reports Strong Financial Performance for Q3 2025

AbbVie Financial Results Overview

AbbVie recently reported impressive financial results for its third quarter, bringing attention to significant achievements in revenue and earnings. The company recorded a diluted EPS of $0.10 on a GAAP basis, which is an 88.6 percent decrease compared to the previous year. However, on an adjusted basis, the diluted EPS was $1.86, marking a decrease of 38.0 percent. These figures incorporate an adverse effect of $1.50 per share due to expenses related to acquired IPR&D and milestone payments.

Noteworthy Financial Metrics

The pharmaceutical giant also reported net revenues of $15.776 billion, representing a 9.1 percent increase year-over-year. On an operational basis, excluding adjustments for currency fluctuations, revenue growth was recorded at 8.4 percent. Within this, the immunology portfolio generated robust sales of $7.885 billion, showing an 11.9 percent increase on a reported basis, boosted by strong performances from Skyrizi and Rinvoq.

Growth Across Various Portfolios

The revenues from AbbVie’s various segments demonstrated growth, especially in the Neuroscience portfolio, which brought in $2.841 billion, an increase of 20.2 percent on a reported basis. Products like Vraylar and Botox Therapeutic contributed significantly, with revenues of $934 million and $985 million, respectively. The company also noted a robust performance in its oncology segment, despite a slight decline, reporting $1.682 billion.

Revenue Performance by Product

Among AbbVie’s notable products, Skyrizi achieved global revenues of $4.708 billion, while Rinvoq contributed $2.184 billion. Humira's revenue, although still significant, fell to $993 million, reflecting a decline as expected due to the increased competition in the market.

Future Outlook and Dividend Increase

AbbVie has raised its adjusted diluted EPS guidance range for 2025, updating it to $10.61 - $10.65, which considers the unfavorable impact mentioned earlier. This move highlights the firm’s confidence in its operational strength and future growth trajectory. Additionally, AbbVie has announced a dividend increase of 5.5 percent, with the new rate beginning with the dividend payable in early 2026.

Investments and Innovations

The company continues to invest in research and development, underscoring its commitment to delivering innovative medicines. Recently, AbbVie gained FDA approval for Rinvoq's expanded use in treating ulcerative colitis and Crohn's disease, marking a significant advancement in its pipeline. Other ongoing projects include trials related to new indications for various therapies and acquisitions aimed at boosting innovative capabilities.

Acquisition Impact

AbbVie finalized its acquisition of Capstan Therapeutics, enhancing its portfolio with a novel treatment for autoimmune conditions through an in vivo targeted platform. This acquisition aligns with AbbVie's strategy to advance its research in biologics and expand its therapeutic offerings.

Shareholder Value and Community Engagement

In addition to strengthening its product line, AbbVie remains dedicated to returning value to shareholders through consistent dividend increases. With a track record of returning significant cash to its investors since its inception, AbbVie sets a standard in the pharmaceutical industry.

Frequently Asked Questions

What were AbbVie's earnings for Q3 2025?

AbbVie reported a diluted EPS of $0.10 on a GAAP basis and $1.86 on an adjusted basis for Q3 2025.

What is the adjusted EPS guidance for 2025?

AbbVie has raised its adjusted diluted EPS guidance for 2025 to a range of $10.61 to $10.65.

How much revenue did AbbVie generate from immunology products?

The immunology portfolio generated revenues of $7.885 billion in Q3 2025.

Is AbbVie increasing its dividends?

Yes, AbbVie announced a dividend increase of 5.5 percent effective February 2026.

What recent awards has AbbVie achieved in the therapeutic areas?

AbbVie received FDA approval for expanding the use of Rinvoq for treating ulcerative colitis and Crohn's disease.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.